mardi 29 novembre 2022

Study: Alzheimer's drug lecanemab shows moderate benefit for people with mild disease

Study: Alzheimer's drug lecanemab shows moderate benefit for people with mild disease https://ift.tt/OLD13Sf

People on the drug reported a slightly higher rate of side effects such as brain swelling and bleeding revealed during brain scans.

     

Aucun commentaire:

Enregistrer un commentaire